<DOC>
	<DOCNO>NCT01099059</DOCNO>
	<brief_summary>Attention-deficit hyperactivity disorder ( ADHD ) common neurobehavioural disorder childhood . The investigator hypothesize amantadine would beneficial treatment ADHD , could evaluate double blind , randomize , parallel group comparison amantadine ritalin . This six-week , parallel group , randomize clinical trial undertaken outpatient child adolescent clinic Roozbeh Psychiatric Hospital Tehran , Iran April 2010-May 2010 . 50 male female subject , age 6 17 year DSM-IV-TR diagnosis ADHD study population trial . At screening , investigator conduct psychiatric evaluation DSM-IV-TR criterion ADHD Kiddie Schedule Affective Disorders Schizophrenia-Present Lifetime diagnostic interview perform complete medical history physical examination . The diagnosis ADHD confirm child adolescent psychiatrist participant initiate study . All patient newly diagnose . Parents carefully interview ask rate severity DSM-IV-TR ADHD symptom child display home . Children exclude history current diagnosis pervasive developmental disorder , schizophrenia psychiatric disorder ( DSM-IV axis I ) ; current psychiatric comorbidity require pharmacotherapy ; evidence suicide risk mental retardation ( I.Q . &lt; 70 ) . In addition , patient exclude clinically significant chronic medical condition , include organic brain disorder , seizure , current abuse dependence drug within 6 month . Additional exclusion criterion hypertension , hypotension . To participate , parent child willing comply requirement study . After description procedure purpose study , write informed consent obtain patient 's parent guardian . Informed consent receive administration study procedure dispense study medication accordance ethical standard investigative site 's institutional review board Helsinki declaration 1975 , revise 2000 . The protocol approve Institutional Review Board ( IRB ) Tehran University Medical Sciences . Patients randomized receive amantadine ritalin 1 : 1 ratio use computer-generated code . All study subject randomly assign receive treatment use amantadine 100-150 mg depend weight ( 100 mg/day &lt; 30 Kg 150 mg/day &gt; 30 Kg ) ritalin dose 20-30 mg/day depend weight ( 20 mg/day &lt; 30 Kg 30 mg/day &gt; 30 Kg ) ( group 2 ) 6 week double blind , randomize clinical . The principal measure outcome Parent Teacher ADHD Rating Scale-IV use extensively Iran school-age child provide valid measure behavioral abnormality attention trial . Side effect systematically record throughout study assess use checklist comprise 20 side effect include psychic , neurologic , autonomic side effect , administer child psychiatrist day 7 , 21and 42 .</brief_summary>
	<brief_title>Amantadine Versus Ritalin Treatment Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>50 male female subject , age 6 17 year DSMIVTR diagnosis ADHD study population trial . At screening , investigator conduct psychiatric evaluation DSMIVTR criterion ADHD Kiddie Schedule Affective Disorders SchizophreniaPresent Lifetime diagnostic interview perform complete medical history physical examination . Children exclude history current diagnosis pervasive developmental disorder , schizophrenia psychiatric disorder ( DSMIV axis I ) Any current psychiatric comorbidity require pharmacotherapy Any evidence suicide risk mental retardation ( I.Q . &lt; 70 ) . In addition , patient exclude clinically significant chronic medical condition , include organic brain disorder , seizure , current abuse dependence drug within 6 month . Additional exclusion criterion hypertension , hypotension .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Attention-deficit/hyperactivity disorder</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Amantadine</keyword>
	<keyword>Methylphenidate</keyword>
</DOC>